Your browser doesn't support javascript.
loading
Cause-specific mortality in COPD subpopulations: a cohort study of 339 647 people in England.
Whittaker, Hannah; Rothnie, Kieran J; Quint, Jennifer K.
Affiliation
  • Whittaker H; School of Public Health and National Heart and Lung Institute, Imperial College London, London, UK h.whittaker@imperial.ac.uk.
  • Rothnie KJ; Department of Epidemiology, Value Evidence and Outcomes, Global Medical R&D, GlaxoSmithKline Plc, Brentford, UK.
  • Quint JK; School of Public Health and National Heart and Lung Institute, Imperial College London, London, UK.
Thorax ; 79(3): 202-208, 2024 Feb 15.
Article in En | MEDLINE | ID: mdl-37328279
ABSTRACT

BACKGROUND:

Identifying correlates of cause-specific mortality in patients with chronic obstructive pulmonary disease (COPD) may aid the targeting of therapies to reduce mortality. We determined factors associated with causes of death in a primary care COPD population.

METHODS:

Clinical Practice Research Datalink Aurum was linked to Hospital Episode Statistics and death certificate data. People with COPD alive between 1 January 2010 and 1 January 2020 were included. Patient characteristics were defined before the start of follow-up (a) frequency and severity of exacerbations; (b) emphysema or chronic bronchitis; (c) Global Obstructive Lung Disease (GOLD) groups A-D; and (d) airflow limitation. We used Cox Proportional Hazards regression and competing risks to investigate the association between patient characteristics and risk of all-cause, COPD and cardiovascular (CV) mortality.

RESULTS:

339 647 people with COPD were included of which 97 882 died during follow-up (25.7% COPD related and 23.3% CV related). Airflow limitation, GOLD group, exacerbation frequency and severity, and COPD phenotype were associated with all-cause mortality. Exacerbations, both increased frequency and severity, were associated with COPD-related mortality (≥2 exacerbations vs none adjusted HR 1.64, 1.57-1.71; 1 severe vs none adjusted HR 2.17, 2.04-2.31, respectively). Patients in GOLD groups B-D had a higher risk of COPD and CV mortality compared with GOLD group A (GOLD group D vs group A, adjusted HR for COPD mortality 4.57, 4.23-4.93 and adjusted HR for CV mortality 1.53, 1.41-1.65). Increasing airflow limitation was also associated with both COPD and CV mortality (GOLD 4 vs 1, adjusted HR 12.63, 11.82-13.51 and adjusted HR 1.75, 1.60-1.91, respectively).

CONCLUSION:

Poorer airflow limitation, worse functional status and exacerbations had substantial associations with risk of all-cause mortality. Differing results for CV and COPD-related mortality suggests interventions to prevent mortality may need to target particular characteristics or time points in the disease course.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Thorax Year: 2024 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: Thorax Year: 2024 Type: Article Affiliation country: United kingdom